A BILL 
To establish procedures regarding the approval of opioid 
drugs by the Food and Drug Administration. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘FDA Accountability 
4
for Public Safety Act’’. 
5
SEC. 2. APPROVAL AGAINST THE RECOMMENDATION OF 
6
THE FDA ADVISORY COMMITTEE ON OPIOID 
7
DRUGS. 
8
(a) IN GENERAL.—Any approval of an application or 
9
supplement to an application under section 505(b) of the 
10
23:04 Jan 17, 2020
H5632
2 
•HR 5632 IH
Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(b)) 
1
for a drug that is an opioid against the recommendation 
2
of the advisory committee pursuant to section 106 of the 
3
Comprehensive Drug and Recovery Act of 2016 (Public 
4
Law 114–198) shall be made by the Commissioner of 
5
Food and Drugs (referred to in this section as the ‘‘Com-
6
missioner’’) and shall not be delegated. 
7
(b) REPORTS TO CONGRESS.—If the Commissioner 
8
approves a drug as described in subsection (a), the Com-
9
missioner shall— 
10
(1) submit a report to the Committee on 
11
Health, Education, Labor, and Pensions of the Sen-
12
ate and the Committee on Energy and Commerce of 
13
the House of Representatives, and to any member of 
14
Congress that requests the report, that includes— 
15
(A) medical and scientific evidence regard-
16
ing patient safety that clearly supports the 
17
Commissioner’s decision to approve the opioid 
18
drug against the recommendation of the advi-
19
sory committee; and 
20
(B) a disclosure of any potential conflicts 
21
of interest that may exist regarding any official 
22
of the Food and Drug Administration who was 
23
involved in the decision to approve the drug 
24
23:04 Jan 17, 2020
H5632
3 
•HR 5632 IH
prior to the Commissioner’s final decision under 
1
subsection (a); and 
2
(2) at the request of the Committee on Health, 
3
Education, Labor, and Pensions of the Senate or the 
4
Committee on Energy and Commerce of the House 
5
of Representatives, testify before that committee re-
6
garding the Commissioner’s decision to approve the 
7
opioid drug against the recommendation of the advi-
8
sory committee. 
9
(c) PROHIBITION ON MARKETING.—A drug approved 
10
as described in subsection (a) shall not be introduced or 
11
delivered for introduction into interstate commerce until 
12
the report described in subsection (b)(1) has been sub-
13
mitted to Congress. 
14
(d) SCOPE OF ADVISORY COMMITTEE REVIEW.—Sec-
15
tion 106(a)(1)(A) of the Comprehensive Addiction and Re-
16
covery Act of 2016 (Public Law 114–198) is amended— 
17
(1) by inserting ‘‘, or supplement to an applica-
18
tion,’’ after ‘‘application’’ each place such term ap-
19
pears; and 
20
(2) by striking ‘‘of a new’’ and inserting ‘‘for’’. 
21
Æ 
23:04 Jan 17, 2020
H5632
